Abstract

Patients with Alzheimer's disease (AD), a common dementia among the aging population, often also suffer from depression. This comorbidity is poorly understood. Although most forms of AD are not genetically inherited, we have identified a new human mutation in the carboxypeptidase E (CPE)/neurotrophic factor-α1 (NF-α1) gene from an AD patient that caused memory deficit and depressive-like behavior in transgenic mice. This mutation consists of three adenosine inserts, introducing nine amino acids, including two glutamines into the mutant protein, herein called CPE-QQ. Expression of CPE-QQ in Neuro2a cells demonstrated that it was not secreted, but accumulated in the endoplasmic reticulum and was subsequently degraded by proteasomes. Expression of CPE-QQ in rat hippocampal neurons resulted in cell death, through increased ER stress and decreased expression of pro-survival protein, BCL-2. Transgenic mice expressing CPE-QQ did not show any difference in the processing enzyme activity of CPE compared with wild-type mice. However, the transgenic mice exhibited poor memory, depressive-like behavior, severely decreased dendrites in the hippocampal CA3 region and medial prefrontal cortex indicative of neurodegeneration, hyperphosphorylation of tau at Ser396, and diminished neurogenesis in the dentate gyrus at 50 weeks old. All these pathologies are associated with AD and the latter with depression and were observed in 50-week-old mice. Interestingly, the younger CPE-QQ mice (11 weeks old) did not show deficits in dendrite outgrowth and neurogenesis. This study has uncovered a human CPE/NF-α1 gene mutation that could lead to comorbidity of dementia and depression, emphasizing the importance of this gene in cognitive function.

Highlights

  • Alzheimer’s disease (AD) is a common form of dementia among the aging population and about 20–30% of AD patients suffer from depression.[1]

  • Our findings indicate that this human carboxypeptidase E (CPE) mutation could result in neurodegeneration, memory deficits and depression linked to AD

  • Our study showed that phosphorylation of tau using an antibody specific for Ser[396], that is well documented in AD cases,[29] was significantly increased in the results taken together indicate that the CPE-QQ mice have many of the histopathological characteristics of dementia, including AD, as well as diminished neurogenesis characteristic of depression

Read more

Summary

INTRODUCTION

Alzheimer’s disease (AD) is a common form of dementia among the aging population and about 20–30% of AD patients suffer from depression.[1]. # DA134138.1, we found that it was one of the collections of FLJ Human cDNA Database (http://flj.lifesciencedb.jp/top/) and DA134138.1 was from databases uncovered a novel mutation in the CPE/(NF-α1) gene in an expressed sequence tag (EST) reported by the Helix Research Institute, Japan, obtained from the cortex of an AD patient.[19] CPE, first identified as a prohormone processing enzyme,[20,21] is located on chromosome 4 at 4q32.3 in the human genome.[22] CPE is expressed during early embryonic development in rats.[23] It is present in neurons and glial cells[24] and has been demonstrated to be a neuroprotective protein.[17,25] Knockout mice, lacking CPE/NF-α1, exhibit obesity, infertility and type 2 diabetes, reflective of the lack of or reduced levels of bioactive peptides.[24,26] They exhibit severe neurodegeneration in the CA3 region of the hippocampus and have poor cognitive function, including deficits in learning and memory.[17] CPE/NF-α1 has been shown to act extracellularly, through the ERK and Akt signaling pathways to enhance expression of BCL-2, a pro-survival protein, to mediate neuroprotection.[27] These CPE/NF-α1 knockout mice cortex RNA of a 65-year-old male AD patient sequenced for a high throughput studies to identify alternative promoter regions of human genes among normal and diseased patients. Western blot analysis confirmed equivalent levels of CPE-WT and CPE-QQ protein in the cell extracts

MATERIALS AND METHODS
RESULTS
DISCUSSION
Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call